Italian Minister of Health, Roberto Speranza, announced an agreement with AstraZeneca to provide Europe with up to 400 million doses of the vaccine, together with Germany, France and the Netherlands. The vaccine has been developed by the University of Oxford in collaboration with IRBM in Pomezia (Rome). The entrepreneur Piero Di Lorenzo bought IRBM from the American multinational Merck in 2009: an Italian miracle. In the following years significant results have been achieved: a balanced budget, the hiring of one hundred researchers, collaborations with the Italian Istituto Superiore di Sanità, the National Research Council (CNR) and several universities. With a law degree and countless work experiences as a communication professional, the President of IRBM can be called a lobbyist: he is able to use his skills in order to achieve and make others achieve better results. He also co-wrote the book Lezioni di Lobby with the journalist Mino Fuccillo.
Article published on Libero Quotidiano – 14/06/2020